消灭脊灰后期的免疫策略及脊灰疫苗不同免疫程序的安全性比较

摘要/Abstract

摘要： 口服脊髓灰质炎减毒活疫苗（OPV）自20世纪60年代中期以来,被全球绝大多数国家的国家免疫规划（NIP）所采用,大规模接种OPV是全球消灭脊灰行动（GPEI）取得成功的决定性因素。但自进入消灭脊灰后期以后,OPV所导致的严重预防接种异常反应—疫苗相关麻痹型脊髓灰质炎（VAPP）的严重性日益增加。为减少VAPP的发生,世界卫生组织在2015年启动了全球脊灰免疫策略调整工作,要求各国尽快在常规免疫中撤销OPV的2型脊灰病毒成分,并采用至少1剂灭活脊髓灰质炎疫苗（IPV）。本文综述了消灭脊灰后期脊灰免疫策略调整的原因和工作进展,并比较了脊灰疫苗不同免疫程序的安全性,以期为我国的相关工作提供参考。

关键词: 脊髓灰质炎, 脊髓灰质炎疫苗, 疫苗相关麻痹型脊髓灰质炎

Abstract: Oral poliomyelitis attenuate live vaccine (OPV) has been routinely used in most countries’ national immunization programs (NIPs) since the middle of 1960s and is generally recognized as the major factor for the success of the Global Polio Eradication Initiative. However, in 2015, to tackle the rising disease burden of vaccine associated paralytic poliomyelitis (VAPP), the most serious adverse event following immunization of OPV, the World Health Organization launched global withdrawal of the type 2 component of OPV and urged all the member states to include at least one dose of inactived poliovirus vaccine (IPV) in NIPs. This paper summarizes the rationale and progress of immunization strategy transition in polio post-eradication era and compared the safety of different polio vaccination programs.

Key words: poliomyelitis, poliomyelitis vaccine, vaccine associated paralytic poliomyelitis

中图分类号:

熊玮仪，董铎. 消灭脊灰后期的免疫策略及脊灰疫苗不同免疫程序的安全性比较[J]. 中国药物警戒, 2017, 14(2): 90-94.

XIONG Wei-yi ,DONG Duo. Review on the Immunization Strategy in Polio Post-eradication Era and Comparison of the Safety of Polio Vaccination Programs[J]. Chinese Journal of Pharmacovigilance, 2017, 14(2): 90-94.

参考文献

[1] World Health Organization. Polio vaccines: WHO position paper-March 2016[R/OL]. (2016-03-25)[2016-09-28]. http://www.who.int/wer/2016/wer9112.pdf?ua=1.
[2] Beale A J. The development of IPV[M]//History of Vaccine Development. Springer New York, 2011: 179-187.
[3] Sabin A B. Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world[J]. Journal of infectious diseases, 1985, 151(3): 420-436.
[4] Wright P F, Kim-Farley R J, de Quadros C A, et al. Strategies for the global eradication of poliomyelitis by the year 2000[J]. New England journal of medicine, 1991, 325(25): 1774-1779.
[5] World Health Organization. Polio Eradication and Endgame Strategic Plan, 2013-2018[R]. Geneva: WHO, 2013：1-3.
[6] Jorba J. Update on vaccine-derived polioviruses-worldwide[J]. Morbidity and Mortality Weekly Report, 2016, 65(30):763-769.
[7] Griffiths U K, Botham L, Schoub B D. The cost-effectiveness of alternative polio immunization policies in South Africa[J]. Vaccine, 2006, 24(29): 5670-5678.
[8] Thompson K M, Tebbens R J D. Retrospective Cost Effectiveness Analyses for Polio Vaccination in the United States[J]. Risk Analysis, 2006, 26(6): 1423-1440.
[9] Tucker A W, Isaacs D, Burgess M. Cost effectiveness analysis of changing from live oral poliovirus vaccine to inactivated poliovirus vaccine in Australia[J]. Australian and New Zealand journal of public health, 2001, 25(5): 411-416.
[10] Estívariz C F, Anand A, Gary H E, et al. Immunogenicity of three doses of bivalent, trivalent, or type 1 monovalent oral poliovirus vaccines with a 2 week interval between doses in Bangladesh: an open-label, non-inferiority, randomised, controlled trial[J]. The Lancet Infectious Diseases, 2015, 15(8): 898-904.
[11] World Health Assembly. Poliomyelitis. A68/21[EB/OL]. [2016-09-28].http://apps.who.int/gb/ebwha/pdf_files/WHA68/A68_21Add1-en.pdf
[12] Hampton L M. Cessation of Trivalent Oral Poliovirus Vaccine and Introduction of Inactivated Poliovirus Vaccine—Worldwide, 2016[J]. MMWR. Morbidity and Mortality Weekly Report, 2016, 65(35):934-938.
[13] World Health Organization. Meeting of the Strategic Advisory Group of Experts on Immunization, April 2016—conclusions and recommendations[R/OL]. (2016-05-27)[2016-09-28]. http://www.who.int/wer/2016/wer9121.pdf?ua=1.
[14] Resik S, TejedaA, Sutter R W, et al. Priming after a fractional dose of inactivated poliovirus vaccine[J]. New England Journal of Medicine, 2013, 368(5): 416-424.
[15] 世卫组织西太平洋区域办事处. 疫苗安全性事件:沟通应对的管理[M/OL]. [2016-09-28]. http://iris.wpro.who.int/bitstream/handle/10665.1/12552/9789290617419_chi.pdf
[16] Centers for Disease Control and Prevention. Poliomyelitis prevention in the US: introduction of a sequential vaccination schedule of IPV followed by OPV: recommendations of the Advisory Committee on Immunization Practices[J]. Morbidity and Mortality Weekly Report, 1997; 46 (RR-3):1-25.
[17] WHO Consultative Group. The relation between acute persisting spinal paralysis and poliomyelitis vaccine-results of a ten-year enquiry[J]. Bulletin of the World Health Organization, 1982, 60(2): 231-242.
[18] Platt L R, Estívariz C F, Sutter R W. Vaccine-associated paralytic poliomyelitis: a review of the epidemiology and estimation of the global burden[J]. Journal of Infectious Diseases, 2014, 210(suppl 1): 380-389.
[19] Strebel P M, Ion-Nedelcu N, Baughman A L, et al. Intramuscular injections within 30 days of immunization with oral poliovirus vaccine—a risk factor for vaccine-associated paralytic poliomyelitis[J]. New England Journal of Medicine, 1995, 332(8): 500-506.
[20] Oliveira L H, Struchiner C J. Vaccine-associated paralytic poliomyelitis in Brazil, 1989-1995[J]. RevistaPanamericana de SaludPública, 2000, 7(4): 219-224.
[21] Stanley A P, Emmauel V.. 灭活脊髓灰质炎疫苗[M]//Stanley A P, Walter A O, Paul A O主编, 梁晓峰, 罗凤基, 封多佳, 主译. 疫苗学. 北京: 人民卫生出版社, 2011: 663-685.
[22] Iqbal S, Shi J, Seib K, et al. Preparation for global introduction of inactivated poliovirus vaccine: safety evidence from the US Vaccine Adverse Event Reporting System, 2000-2012[J]. The Lancet Infectious Diseases, 2015, 15(10): 1175-1182.
[23] Alexander L N, Seward J F, Santibanez T A, et al. Vaccine policy changes and epidemiology of poliomyelitis in the United States[J]. The Journal of the American Medical Association, 2004, 292(14): 1696-1701.
[24] Strategic Advisory Group of Experts on Immunization. Scientific evidence in support of: Note for the record: 5th meeting of the SAGE Working Group[R/OL].(2012-10-12)[2016-09-28] http://www.who.int/immunization/sage/meetings/2012/november/3__SAGE_WG_Scientific_Evidence22Oct2012.pdf
[25] 罗会明, 余文周, 温宁, 等. 中国脊髓灰质炎疫苗使用历史回顾及免疫策略调整建议[J]. 中国疫苗和免疫, 2014, 20(2): 172-176.
[26] 国家卫生计生委. 国家卫生计生委关于停用三价脊髓灰质炎减毒活疫苗的通知[EB/OL]. (2016-04-29)[2017-01-25].http://www.hncdc.com/Article/ShowArticle.asp?ArticleID=8322
[27] 温宁, 王兆南, 樊春祥, 等. 免疫规划专业人员对脊髓灰质炎疫苗使用知识态度行为的调查[J]. 中国疫苗和免疫, 2013, 18(6): 523-526.
[28] 褚尧竹, 周玉清, 张旋, 等. 中国六省份儿童监护人脊髓灰质炎疫苗知识和接种意愿调查[J]. 中国疫苗和免疫, 2016, 22(3): 246-251.
[29] 刘大卫, 郭飚, 曹玲生, 等. 全国2005-2006年疑似预防接种异常反应监测分析[J]. 中国计划免疫, 2007, 13(6): 505-513.
[30] 武文娣, 刘大卫, 吴冰冰, 等. 全国2007-2008年疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫, 2009 (6): 481-490.
[31] 武文娣, 刘大卫, 李克莉, 等. 全国2009年疑似预防接种异常反应监测分析[J]. 中国疫苗和免疫, 2011, 17(2): 99-108.
[32] 武文娣, 刘大卫, 李克莉, 等. 中国2010年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2012, 18(5): 385-397.
[33] 武文娣, 李克莉, 郑景山, 等. 中国2011年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2013, 19(2): 97-109.
[34] 武文娣, 刘大卫, 李克莉, 等. 中国2012年疑似预防接种异常反应监测数据分析[J]. 中国疫苗和免疫, 2014, 20(1): 1-12.
[35] 叶家楷, 李克莉, 许涤沙, 等. 中国2013年疑似预防接种异常反应信息管理系统数据分析[J]. 中国疫苗和免疫, 2015, 21(2): 121-131.
[36] 叶家楷, 李克莉, 许涤沙, 等. 中国2014年疑似预防接种异常反应信息管理系统监测数据分析[J]. 中国疫苗和免疫, 2016, 22(2): 125-137.